Aurobindo Pharma Q1 net profit up by 39.52 percent to Rs 636 crore

"We have started the year with a healthy performance. Enhancing our quality management practices and adhering to the regulatory requirements continues to be our highest priority," Aurobindo Pharma MD N Govindarajan said.

New Delhi: Drug firm Aurobindo Pharma on Wednesday reported a 39.52% rise in consolidated net profit to Rs 635.68 crore for the quarter ended June 2019, mainly on account of robust sales in the US and Europe.

The company had posted a net profit of Rs 455.59 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a BSE filing.

Consolidated total revenue from operations rose to Rs 5,444.60 crore for the quarter under consideration as against Rs 4,250.27 crore for the same period a year ago, it added.

Also Read: Aurobindo Pharma in focus on the launch of a generic version of Sensipar tablets in the US

"We have started the year with a healthy performance. Enhancing our quality management practices and adhering to the regulatory requirements continues to be our highest priority," Aurobindo Pharma MD N Govindarajan said.

During the quarter, the company commissioned Eugia's manufacturing facility and launched five oncology and hormonal products in the US market, he added.

"Our differentiated product basket is progressing well and we are in the process of starting clinical trials for our first biosimilar in Q2FY20," Govindarajan said.

US formulations revenue stood at Rs 2,688.4 crore for the first quarter of the current fiscal as against Rs 1,889.6 crore in Q1FY19, registering a robust growth of 42.3%, the company said.

Europe formulations revenue stood at Rs 1,391.6 crore, up 16.1% year-on-year.

Also Read: Aurobindo Pharma pulled up by USFDA for repeated CGMP failures